---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-082723"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:59:45.773376+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma appoints Juliette Audet as CBO, effective April 1, 2024

## Summary
- Juliette Audet appointed Chief Business Officer, effective April 1, 2024.
- Audet resigns from Board of Directors; no disagreement with company.
- Audet was a Partner at Forbion and previously on the Board since 2020.
- Company expects two pivotal readouts for obicetrapib in 2024.

## SEC filing metadata
- accession: 0001193125-24-082723
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/0001193125-24-082723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/d800417d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-082723
- JSON: https://secwatch.observer/filing/0001193125-24-082723.json
- Plain text: https://secwatch.observer/filing/0001193125-24-082723.txt

## Key facts
- Executive change
  Juliette Audet resigned as Director at NewAmsterdam Pharma Co N.V..
  - Action: resigned
  - Role: Director
  source text: In connection with Ms. Audet’s appointment as CBO, the Company’s board of directors (the “Board”) and Ms. Audet determined, as of March 28, 2024, that she will resign, effective April 1, 2024, from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/0001193125-24-082723-index.htm
- Executive change
  Juliette Audet was appointed as Chief Business Officer at NewAmsterdam Pharma Co N.V..
  - Action: appointed
  - Role: Chief Business Officer
  source text: On April 1, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) announced the appointment of Juliette Audet as Chief Business Officer (“CBO”) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/0001193125-24-082723-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.